The present invention provides a transgenic mouse and an animal model that is used to assay for the inhibition or activation of the Cnr2 gene and methods for screening drugs to treat or prevent psychosis, anxiety, depression, autism disorders, drug addiction, Parkinsons disease and/or Alzheimers disease, multiple sclerosis, inflammation, stroke, osteoporosis, scleroderma or cancer.